Search

Displaying results 3491 - 3500 of 5451 in total
  1. Drug

    Sapacitabine

    go.drugbank.com/drugs/DB06365
    Investigational

  2. Drug

    Raxibacumab

    go.drugbank.com/drugs/DB08902
    ApprovedInvestigational

    Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA tech...

  3. Drug

    Cycloserine

    go.drugbank.com/drugs/DB00260
    ApprovedInvestigational

    Antibiotic substance produced by Streptomyces garyphalus.

    Products: CICLOSERINA 250 MG CAPSULAS, SIKLOCAP 250 MG KAPSUL, 500 ADET
  4. Drug

    Azathioprine

    go.drugbank.com/drugs/DB00993
    ApprovedInvestigational

    Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index. Azathioprine is us...

    Products: AZATHIOPRIN HEU 50MG NET, IMURAN® 50 MG
  5. Drug

    Stannous chloride

    go.drugbank.com/drugs/DB11056
    Approved

    Tin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities [A32700].

  6. Drug

    Valinomycin

    go.drugbank.com/drugs/DB14057
    Experimental

    (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies. … It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring.

  7. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. … APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation.

  8. Drug

    Somapacitan

    go.drugbank.com/drugs/DB15093
    ApprovedInvestigational

    [A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.

    Products: SOGROYA® 5MG/1.5ML, Sogroya® 5 mg/1.5 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem (1 adet)
  9. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797]

    Products: RAPTIVA ®125 MG
  10. Drug

    Asenapine

    go.drugbank.com/drugs/DB06216
    ApprovedInvestigational

    It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.

    Products: SAPHRIS SUBLINGUAL TABLET 5MG, SYCREST 5MG DILALTI TABLET, 100 TABLET